2017 Aug. 49 (8):1211-1218. Genetic susceptibility in childhood acute lymphoblastic leukemia. News-Medical. [Medline]. Br J Haematol. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 5(5):384-94. J Clin Oncol. 1-8. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Accessed: February 20, 2020. 2012 Jan 11. Researchers receive innovative grants to understand the biological underpinnings of blood cancers, Combination regimen improves overall survival in certain patients with AML, New leukemia immune profiles predict drug resistance, positive responses to immunotherapy, Study could refine treatment recommendations for younger adult patients with acute leukemia, New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia, Mapping immune landscape of hematological malignancies may help improve cancer therapies, Two potent small molecules appear to suppress tumor growth in multiple cancers, Researchers call for caution of using CAR-T immunotherapy against AML, Viral loads peak before symptom onset in COVID-19, Study reveals substantial adverse outcomes in patients hospitalized with COVID-19, More evidence Pangolin not intermediary in transmission of SARS-CoV-2 to humans, Vitamin D deficiency may predict COVID-19 seroconversion, New findings could improve investigation of T cell response to COVID-19, Eliminating the cold chain with COVID-19 molecular transport media. [Guideline] Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Fiere D, Extra JM, David B, Witz F, Vernand JP, Gastaut JA, et al. Learn more about ALL. [Medline]. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. This website also contains material copyrighted by 3rd parties. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. The finding that the improved prognosis associated with AML with mutated CEBPA is associated with biallelic, but not single, mutations of the gene84-88  has resulted in a change in that disease definition to require biallelic mutations. N Engl J Med. These latter features allow this indolent entity to be distinguished from T-lymphoblastic lymphoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 7005). PB monocytes must be <1 × 109/L. 2013 Sep 20. Cambridge, MA. [Medline]. Blood. There is a major change in the diagnostic criteria for myeloid neoplasms with erythroid predominance (erythroid precursors ≥50% of all BM cells). J Clin Oncol. Fiere D, Archimbaud E, Extra JM, Marty M, David B, Witz F, et al. 26 (11):1843-9. Marqibo (vincristine liposomal) [package insert]. These cases may simulate CMML. 2017 Jun 22. Some patients, especially those with EBF1-PDGFRB translocations, have shown remarkable responses to TKI therapy, even after failing conventional therapy.125, Patients with BCR-ABL1–like ALL show a high frequency of loss of IKZF1 and CDKN2A/B, but these deletions also occur in high frequency in other types of ALL as well.121.